Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mocravimod - Priothera

Drug Profile

Mocravimod - Priothera

Alternative Names: KRP-203

Latest Information Update: 08 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kyorin Pharmaceutical
  • Developer Kyorin Pharmaceutical; Novartis; Priothera
  • Class Anti-inflammatories; Propylene glycols
  • Mechanism of Action Sphingosine 1 phosphate receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes - Crohn's disease; Cutaneous lupus erythematosus; Ulcerative colitis

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase II Crohn's disease; Cutaneous lupus erythematosus; Ulcerative colitis
  • Phase I/II Diffuse large B cell lymphoma

Most Recent Events

  • 27 Nov 2023 Mocravimod receives Orphan Drug status for improvement of the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with hematologic malignancies in USA
  • 05 Jun 2023 Phase-I/II clinical trials in Diffuse large B cell lymphoma (Second-line therapy or greater) in Germany (PO) (EudraCT2022-003618-35)
  • 10 Apr 2023 Mocravimod - Priothera is available for licensing as of 10 Apr 2023. info@priothera.com
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top